2026年6月最新影响因子数据已更新,欢迎查询使用。如果您对期刊系统有任何需求或者问题,欢迎反馈给我们。
| 热门AI工具: |
论文引言生成
New
AI 写作痕迹检测
Hot
学术改写降重
论文讨论生成
参考文献挖掘工具
审稿意见辅助撰写
|
查看更多AI工具 >> |
| 近期推荐: | 热 全流程投稿协助套餐服务 | 热 SCI论文AI润色+人工QC服务 | 热 Springer Nature特刊征稿 |
| |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字![]() | Liver Cancer LIVER CANCER (此期刊被最新的JCR期刊SCIE收录) LetPub评分 8.5
51人评分
我要评分
声誉 9.9 影响力 7.7 速度 7.0 | |||||||||||||||||||||
| 期刊ISSN | 2235-1795 | 安装APP,查看期刊最新消息
| ||||||||||||||||||||
| E-ISSN | 1664-5553 | |||||||||||||||||||||
| 2025-2026最新IF (数据来源于网友提供) | 注册或登录后,查看IF | |||||||||||||||||||||
| 实时影响因子 | 截止2026年9月20日:6.214 | |||||||||||||||||||||
| 2025-2026自引率 | 10.5%点击查看自引率趋势图 | |||||||||||||||||||||
| 五年IF (数据来源于网友提供) | 11.502数据由网友[swift_comet]收集提供 | |||||||||||||||||||||
| h-index | 25 | |||||||||||||||||||||
| CiteScore ( 2026年6月最新版) |
| |||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||
| 期刊官方网站 | https://www.karger.com/Journal/Home/255487 | |||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||
| 期刊投稿网址 | https://www.manuscriptmanager.net/sLib/v4/login.php?paramScreen=bcN+I3CS9qwx940f/BPvJ/MzoRzVWdbdT6ew8aLp8Yk= | |||||||||||||||||||||
| 该期刊中国学者近期发文 - New | Lenvatinib versus Sorafenib in First-Line Treatment of Older Patients with Unresectable Hepatocellular Carcinoma: A Subgroup Analysis of the REFLECT Trial Author: Kudo, Masatoshi; Vogel, Arndt; Evans, Thomas R. Jeffry; Ma, Yuk Ting; Daniele, Bruno; Baron, Ari David; Mahipal, Amit; Qin, Shukui; Blanc, Jean Frederic; Lopez Lopez, Carlos; Cheng, Ann-Lii; Choo, Su Pin; Piscaglia, Fabio; Mody, Kalgi; Ren, Min; Chan, Stephen Lam Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000553375 Outcomes by Comorbidities with Tremelimumab and Durvalumab in the Randomized, Controlled Phase 3 HIMALAYA Study in Unresectable Hepatocellular Carcinoma Author: Rimassa, Lorenza; Dayyani, Farshid; Kelley, Robin K.; Sangro, Bruno; Chan, Stephen L.; Nakamura, Hitomi; Clark, Lucy; Xynos, Ioannis; Abou-Alfa, Ghassan K Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/lic/admag001 Curative Locoregional Therapy following Objective Response to Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma Author: Shao, Yu-Yun; Chen, San-Chi; Rau, Kun-Ming; Lee, Teng-Yu; Chan, Stephen L.; Liu, Ken; Lai, Hsueh-Chou; George, Jacob; Gofton, Cameron; Putraveephong, Siraphong; Feng, Yin-Hsun; Lee, Ming-Yang; Lee, Jie XinJoycelyn; Tai, David; Lee, Suat Ying; Chen, Yen-Hao; Wu, Tsung-Che; Mo, Lein-Ray; Wi, Wan Zamaniah; Lesmana, Cosmas Rinaldi A.; Hui, Cheng Vai; Li, Shu Sen Sam; Hasan, Irsan; Chan, Landon L.; Nguyen, Melinda; De Silva, Madhawa; Chuang, Chien-Huai Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/lic/admag004 Targeting Plasmacytoid Dendritic Cell-Invariant Natural Killer T Axis through TLR7 Agonist to Enhance Anti-Tumor Immune Therapy in Residual Cancer after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma Author: Zheng, Sui; Luo, Wanrong; Luo, Man; Zhang, Yixin; Su, Xiaoqing; Xiong, Shiyu; Li, Rumei; Wei, Qiuxia; Tang, Haifeng; Shen, Zhibin; Zhang, Wenyue; Luo, Baoming Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/lic/admag003 | |||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足Liver Cancer的语言要求,还能让Liver Cancer编辑和审稿人得到更好的审稿体验,让稿件最大限度地被Liver Cancer编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||
| 通讯方式 | ALLSCHWILERSTRASSE 10, BASEL, SWITZERLAND, CH-4009 | |||||||||||||||||||||
| 出版商 | S. Karger AG | |||||||||||||||||||||
| 涉及的研究方向 | Medicine-Oncology | |||||||||||||||||||||
| 出版国家或地区 | SWITZERLAND | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | ||||||||||||||||||||||
| 出版年份 | 0 | |||||||||||||||||||||
| 年文章数 | 66点击查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 100.00% | |||||||||||||||||||||
| 研究类文章占比: 文章 ÷(文章 + 综述) | 86.36% | |||||||||||||||||||||
| WOS期刊JCR分区 ( 2025-2026年最新版) | 注册或登录后,查看WOS分区等级 | |||||||||||||||||||||
| 期刊分区表预警名单 | 2026年03月发布的新锐学术版:不在预警名单中 2025年03月发布的2025版:不在预警名单中 2024年02月发布的2024版:不在预警名单中 2023年01月发布的2023版:不在预警名单中 2021年12月发布的2021版:不在预警名单中 2020年12月发布的2020版:不在预警名单中 | |||||||||||||||||||||
| 《新锐期刊分区表》 ( 2026年3月发布) | 点击查看期刊分区表趋势图
| |||||||||||||||||||||
| 期刊分区表 ( 2025年3月升级版) |
| |||||||||||||||||||||
| 期刊分区表 ( 2023年12月旧的升级版) |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE) Scopus (CiteScore) Directory of Open Access Journals (DOAJ) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2235-1795%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验: 16 Weeks | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验: | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)后论文在Liver Cancer顺利发表。
快看看作者怎么说吧:服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Lenvatinib versus Sorafenib in First-Line Treatment of Older Patients with Unresectable Hepatocellular Carcinoma: A Subgroup Analysis of the REFLECT Trial Author: Kudo, Masatoshi; Vogel, Arndt; Evans, Thomas R. Jeffry; Ma, Yuk Ting; Daniele, Bruno; Baron, Ari David; Mahipal, Amit; Qin, Shukui; Blanc, Jean Frederic; Lopez Lopez, Carlos; Cheng, Ann-Lii; Choo, Su Pin; Piscaglia, Fabio; Mody, Kalgi; Ren, Min; Chan, Stephen Lam Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000553375 PubMed DOI |
| 2. | Outcomes by Comorbidities with Tremelimumab and Durvalumab in the Randomized, Controlled Phase 3 HIMALAYA Study in Unresectable Hepatocellular Carcinoma Author: Rimassa, Lorenza; Dayyani, Farshid; Kelley, Robin K.; Sangro, Bruno; Chan, Stephen L.; Nakamura, Hitomi; Clark, Lucy; Xynos, Ioannis; Abou-Alfa, Ghassan K Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/lic/admag001 DOI |
| 3. | Curative Locoregional Therapy following Objective Response to Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma Author: Shao, Yu-Yun; Chen, San-Chi; Rau, Kun-Ming; Lee, Teng-Yu; Chan, Stephen L.; Liu, Ken; Lai, Hsueh-Chou; George, Jacob; Gofton, Cameron; Putraveephong, Siraphong; Feng, Yin-Hsun; Lee, Ming-Yang; Lee, Jie XinJoycelyn; Tai, David; Lee, Suat Ying; Chen, Yen-Hao; Wu, Tsung-Che; Mo, Lein-Ray; Wi, Wan Zamaniah; Lesmana, Cosmas Rinaldi A.; Hui, Cheng Vai; Li, Shu Sen Sam; Hasan, Irsan; Chan, Landon L.; Nguyen, Melinda; De Silva, Madhawa; Chuang, Chien-Huai Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/lic/admag004 DOI |
| 4. | Targeting Plasmacytoid Dendritic Cell-Invariant Natural Killer T Axis through TLR7 Agonist to Enhance Anti-Tumor Immune Therapy in Residual Cancer after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma Author: Zheng, Sui; Luo, Wanrong; Luo, Man; Zhang, Yixin; Su, Xiaoqing; Xiong, Shiyu; Li, Rumei; Wei, Qiuxia; Tang, Haifeng; Shen, Zhibin; Zhang, Wenyue; Luo, Baoming Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/lic/admag003 DOI |
| 5. | Prognostic Significance of Response Dynamics in Atezolizumab plus Bevacizumab-Treated Hepatocellular Carcinoma: A Multicenter Real-World Validation Study Author: Guan, Renguo; Huang, Kaijun; Zheng, Zehao; Zhao, Zhen; Tang, Meishi; Jin, Haosheng; Mei, Jie; Lin, Ye Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/lic/admag002 DOI |
| 6. | Atezolizumab plus Bevacizumab versus Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Stratified by the CRAFITY Score: An International Multicenter Study Author: Ueno, Masayuki; Su, Yung-Yeh; Takai, Atsushi; Huang, Yi-Hsiang; Morimura, Hiroki; Nishijima, Norihiro; Lin, Shi-Ming; Chang, Ching-Wei; Iwamoto, Satoru; Nagatomo, Shu; Lai, Hsueh-Chou; Mitani, Takeshi; Ikeda, Atsuyuki; Uenoyama, Yoshito; Umeda, Makoto; Chen, San-Chi; Chuang, Chien-Huai; Lai, Shiue-Wei; Lee, Teng-Yu; Nakano, Shigeharu; Dai, Chia-Yen; Goto, Tomoyuki; Su, Tung-Hung; Hsu, Ching Sheng; Lo, Ching-Chu; Takeda, Haruhiko; Osaki, Yukio; Hatano, Etsuro; Lee, Pei-Chang; Lin, Po-Ting; Wang, Hung-Wei; Hsu, Wei-Fan; Liu, Tsung-Hao; Seno, Hiroshi Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000552808 PubMed DOI |
| 7. | Reply to Methodological Concerns in 'Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma' Author: Yang, Da-Long; Huang, Jian-Li; Qin, Hong-Gui; Ma, Liang; Zhong, Jian-Hong Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000553001 PubMed DOI |
| 8. | Reply to the Comment on the Article Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor Based Combination Therapy for Unresectable Hepatocellular Carcinoma Author: Huang, Zhi-Hao; Huang, Jian-Li; Lin, Lei-Po; Yang, Da-Long; Ma, Liang; Zhong, Jian-Hong Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000553004 PubMed DOI |
| 9. | Transarterial Chemoembolization plus Systemic Therapy versus Transarterial Chemoembolization alone for Unresectable, Nonmetastatic Hepatocellular Carcinoma: Meta-Analysis and Trial Sequential Analysis from Randomized Controlled Trials Author: Liu, Jiaxi; Zhai, Huan; Shang, Liqi; Wang, Peng; Liu, Jiaxuan; Wang, Luke; You, Qiwen; Qin, Meiwen; Ma, Yanan; Shao, Haibo Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000552229 PubMed DOI |
| 10. | Addition of Intra-Arterial Therapy to Immunotherapy Improves Outcomes in Unresectable Hepatocellular Carcinoma: Taiwan Multicenter Cohort Study Author: Lee, Teng-Yu; Lee, Pei-Chang; Shen, Ying-Chun; Hsu, Wei-Fan; Lai, Shiue-Wei; Chang, Ching-Wei; Su, Yung-Yeh; Su, Tung-Hung; Lin, Po-Ting; Dai, Chia-Yen; Hsu, Ching-Sheng; Chen, San-Chi; Rau, Kun-Ming; Lee, I-Cheng; Jhan, Song-Ru; Liu, Tsung-Hao; Lai, Hsueh-Chou; Wang, Tsang-En; Lin, Shi-Ming; Liang, Po-Cheng; Tseng, Cheng-Hao; Chang, Pi-Yi; Wu, Shu-Cheng; Wang, Hung-Wei; Lee, Shou-Wu; Huang, Yi-Hsiang Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000552375 PubMed DOI |
|
|
|
投稿状态统计: 我要评分: | ||||||||||||||||
| 投稿前担心稿件结构或语言不够规范?试试稿件自查工具,一键检测 >> | ||||||||||||||||
|
||||||||||||||||
同领域作者分享投稿经验:共0条 |
||||||||||||||||
|
|

联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2026 中国: LetPub上海 网站备案号:沪ICP备10217908号-1
沪公网安备号:31010402006960 (网站)31010405000484 (蝌蝌APP)
增值电信业务经营许可证:沪B2-20211595 网络文化经营许可证:沪网文[2023]2004-152号
礼翰商务信息咨询(上海)有限公司 办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室